BlackRock, Inc. has disclosed a significant ownership stake in Workiva Inc. through an amended Schedule 13G filing. The filing, dated November 4, 2026, reveals that BlackRock beneficially owns 8,003,681 shares of Workiva's Class A stock, representing 15.7% of the total outstanding shares. This substantial stake could influence strategic decisions at Workiva and reflects BlackRock's ongoing commitment to its investment strategy.
BlackRock, Inc., a leading investment management firm, operates under the SIC classification of Security Brokers, Dealers & Flotation Companies. The company is publicly traded on the New York Stock Exchange under the ticker symbol BLK. BlackRock is recognized for its extensive portfolio management and investment advisory services, making it a key player in the financial services industry.
The amended filing indicates that BlackRock's ownership includes 7,898,342 shares with sole voting power and the same number for sole dispositive power. The filing also notes that one of BlackRock's entities, the iShares Core S&P Small-Cap ETF, holds more than 5% of Workiva's outstanding shares. The filing does not provide further details on any strategic intentions behind this ownership stake.
This update may impact various stakeholders, including Workiva's management, shareholders, and competitors. As BlackRock increases its influence over Workiva, the company may face pressure to align its strategies with the interests of its largest shareholder. Competitors in the security brokers and dealers sector may also need to reevaluate their positions in light of BlackRock's significant investment.
Looking ahead, the filing does not specify what actions may follow this disclosure. It remains to be seen whether BlackRock will engage more actively with Workiva's management or if this stake will lead to any changes in corporate governance or strategy.
Read Next
Wassil Jim Reports Stock Transactions for Vaxcyte, Inc.
Cowan Elvia Reports Stock Transactions in SEC Filing
Saiki Julie Reports New Stock Transactions at Azora Therapeutics
Davidson Acquires Over 524,000 Shares of Azora Therapeutics
CBL & Associates Properties Announces New Stock Buyback Plan
Rothblatt amends Schedule 13G, reveals 4% stake in United Therapeutics








